Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2017 07:00 ET | Source: uniQure N.V.

uniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates

– Effective Transduction Achieved After Readministration of Gene Transfer – – Preclinical Data Presented Today at American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in...
May 10, 2017 07:00 ET | Source: uniQure N.V.

uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates

-- Strong Dose-Dependent Transduction in All Animals Tested Regardless of the Level of Anti-AAV5 Antibodies at Pre-Administration -- -- Data Suggests AAV5 Gene Therapies May be Viable...
May 09, 2017 07:00 ET | Source: uniQure N.V.

uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 09, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company developing transformative therapies for patients with...
May 01, 2017 07:00 ET | Source: uniQure N.V.

uniQure Announces Company Presentations at Upcoming May Conferences

-- Investor breakfast event and webcast at ASGCT on Friday, May 12 at 7:00 a.m. EDT -- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 01, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE),...
April 26, 2017 07:00 ET | Source: uniQure N.V.

uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at CHDI’s 12th Annual Huntington’s Disease Therapeutics Conference

-- One-time Administration of AMT-130 Demonstrates for the First Time Efficacy in Large Animal Model -- Strong Dose-Dependent Reduction of Mutant Huntingtin Protein and Widespread Vector Distribution...
April 25, 2017 07:05 ET | Source: uniQure N.V.

uniQure Receives European Medicines Agency Priority Medicines (PRIME) Designation for AMT-060 in Hemophilia B

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 25, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
April 24, 2017 16:05 ET | Source: uniQure N.V.

uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 24, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
April 20, 2017 07:00 ET | Source: uniQure N.V.

uniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe

-- Marketing Authorization for Glybera® to Expire on October 25, 2017 ---- Company Maintains Focus on Core Programs in Hemophilia B, Huntington’s Disease and Congestive Heart Failure --LEXINGTON,...
April 04, 2017 07:42 ET | Source: uniQure N.V.

uniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 04, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...
April 03, 2017 07:00 ET | Source: uniQure N.V.

uniQure Announces Presentations at Upcoming April Conferences

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, April 03, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with...